A Napolitano,A De Vita,R L Jones
A Napolitano
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
淋巴瘤：诊断、治疗和随访的ESMO临床实践指南
T A Eyre,K Cwynarski,F d&#x;Amore et al.
T A Eyre et al.
Current and future treatments for low risk gestational trophoblastic neoplasia [0.03%]
低危妊娠滋养细胞肿瘤的当前和未来的治疗方法
Michael J Seckl,Ehsan Ghorani
Michael J Seckl
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials [0.03%]
HER2阳性早期乳腺癌降阶梯新辅助治疗预后的预测：三项德国乳腺和卵巢癌工作组（WSG）临床试验的汇总分析
M Graeser,O Gluz,C Zu Eulenburg et al.
M Graeser et al.
Background: We analyzed outcomes and survival predictors in three WSG randomized de-escalation trials (ADAPT-HR-/HER2+, ADAPT-TP, TP-II) in HER2+ early breast cancer (eBC) investigating short (12-week) neoadjuvant treatme...
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis [0.03%]
关于因1级间质性肺疾病/肺炎恢复后的泰圣奇再治疗的汇总分析
H S Rugo,E Tokunaga,H Iwata et al.
H S Rugo et al.
Purpose: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate treatment for multiple solid tumors, carries risk of interstitial lung disease/pneumonitis (ILD). Management guidelines generally mandate interrupting T-...
Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues [0.03%]
Arenhardt和Nogueira-Rodrigues关于“PAOLA-1长期随访及卵巢癌PARP治疗后的治疗策略演变”的来信回复
I Ray-Coquard,C Cropet,P Harter et al.
I Ray-Coquard et al.
Can radiology be first to use prognostic deep learning models for oncological treatment? [0.03%]
放射学能否率先使用预测性深度学习模型进行肿瘤治疗？
K Cyll,O-J Skrede,A Kleppe
K Cyll
Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis [0.03%]
关于NATALEE最终无病生存分析的来信回复文章
G N Hortobagyi,M Ruiz Borrego
G N Hortobagyi
Cancer of Unknown Primary Site and TNM Staging: A New Paradigm for Patient Management [0.03%]
未知原发灶癌症与TNM分期：患者管理的新模式
F Anthony Greco
F Anthony Greco
Cancer of unknown primary site (CUP) is a syndrome of many different metastatic cancers arising from clinically occult primary tumors. There has been no established staging system applicable since an anatomical primary tumor has not been po...